2159. The Impact of a national intervention on hospital-acquired bloodstream infection rates in Israeli intensive care units
Session: Poster Abstract Session: HAI: Device Related Infections
Saturday, October 7, 2017
Room: Poster Hall CD
  • poster national clabsi prevention 260917 (2).pdf (868.3 kB)


    The Impact of a National Intervention on Hospital-Acquired Bloodstream Infection Rates in Israeli Intensive Care Units


    Hospital-acquired bloodstream infections and the subclass of central line-associated bloodstream infections (CLABSI) are associated with considerable morbidity, mortality, and healthcare costs. The burden of central line-associated bloodstream infections (CLABSI) in Israeli intensive care units (ICUs) has not been previously described. The present study aimed to assess the impact of implementing the NHSN practice recommendations for CLABSI prevention in Israeli ICUs.


    A prospective, national, ongoing interventional program was conducted from January 2012 until December 2016 in all adult and pediatric ICUs in Israel, The NHSN practice recommendations were introduced and implemented during 2012, including of insertion and maintenance bundles, education, outcome surveillance and feedback on CLABSI rates. The Israeli national nosocomial surveillance program is a mandatory, confidential system. Data on CLABSI and non CLABSI events were collected monthly. Feedback was disseminated to all hospitals twice yearly. Between January 2012 and December 2015, definitions were based on the 2012 NNIS/NHSN system; they were updated in 2016.


    114 ICUs in 30 hospitals contributed to 1,727,000 patient days (PD). During the study period, a total of 6741 acquired BSI events were reported, 63% were non-CLABSI. In total, 2488 cases of CLABSI were observed over 447,436 central line days (CLD). The pooled mean baseline total BSI and CLABSI rates were 5/1000 PD and 7.4/1000 CLD, respectively, and these decreased significantly to 3.3/ 1000PD (p<0.001) and 4/1000 CLD (p<0.001), respectively in 2016. (graph 1 and 2)  


    Following a national intervention, significant decreases in both total BSI and CLABSI rates were observed.  The large proportion of non-CLABSI BSI highlights the necessity to evaluate causes of non-CLABSI events and implement prevention measures.

    Figure 1: Mean incidence rates of CLABSI and non-CLABSI per ICU type in 114 ICUs, Israel, 2012-2016

     Figure 2: Mean incidence rates of CLABSI per ICU type in 114 ICUs, Israel, 2012-2016


    Debby Ben-David, MD1, Pnina Shitrit, MD2, Bina Rubinovich, MD3, Dror Marchaim, MD4, Ester Solter, MA5, Azza Vaturi, MA6, Elizabeth Temkin, PhD7, Yehuda Carmeli, MD, MPH8 and Mitchell J. Schwaber, MD5, (1)National Center for Infection Control, Ministry of health, Tel Aviv, Israel, (2)Infection Control Unit, Meir Medical Center, Kfar Saba, Israel, (3)Rabin Medical Center, Petach Tikva, Israel, (4)Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, Israel, (5)National Center for Infection Control, Tel Aviv, Israel, (6)National Center for Infection Control, Ministry of Health, Tel Aviv, Israel, (7)Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, (8)National Center Antibiotic Resistance, Ministry of Health,Israel, Tel Aviv, Israel


    D. Ben-David, None

    P. Shitrit, None

    B. Rubinovich, None

    D. Marchaim, None

    E. Solter, None

    A. Vaturi, None

    E. Temkin, None

    Y. Carmeli, None

    M. J. Schwaber, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.